Collectively, these findings suggest that inhibition of tumor-intrinsic ORMDL3 amplifies anti-tumor immunity by increasing ISGs expression in TME and promoting cytotoxic CD8+ T cell activation. This evidence concerns the gene CD8A and neoplasm.